Rare diseases
Investigational molecules
Locations
Back to Germany93 clinical trials in Darmstadt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis
GermanyStudy on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis
GermanyStudy on the Safety and Effectiveness of APG777 for Patients with Moderate-to-Severe Atopic Dermatitis
GermanyStudy on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
GermanyStudy on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
GermanyStudy on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
GermanyStudy on the Effects of Sonelokimab for Adults with Moderate to Severe Hidradenitis Suppurativa
GermanyStudy on the Long-Term Safety and Effectiveness of Nemolizumab for Patients with Prurigo Nodularis
GermanyStudy on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines
GermanyStudy of ritlecitinib (50 mg and 100 mg daily) compared to placebo in adults with nonsegmental vitiligo
GermanyStudy on Rezpegaldesleukin for Treating Moderate-to-Severe Atopic Dermatitis in Adults
GermanyStudy on Benralizumab for Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with Frequent Exacerbations
GermanyThe busiest research cities in the country
What the registry says about research in the country
Extensive research focusing on plaque psoriasis and hidradenitis suppurativa, evaluating new therapeutic approaches for chronic skin conditions. Multiple trials are testing novel treatments for moderate to severe cases.
Several innovative compounds being tested including ESK-001, remibrutinib, and JNJ-77242113.
Comprehensive studies addressing severe asthma and COPD, with particular attention to treatments for patients with eosinophilic phenotypes and those requiring advanced care options.
Trials evaluating new inhalation therapies and biological treatments for better disease control.
Advanced studies in acute myeloid leukemia, investigating combination therapies for patients ineligible for intensive chemotherapy. Focus on targeted treatments for specific genetic mutations.
Investigating innovative approaches including revumenib in combination with established treatments.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
